Senior Correspondent, London
Ben's Feed
Aug 28, 2014

GSK Ebola vaccine fast-tracked into U.S., UK and African trials

LONDON/NEW YORK (Reuters) – An experimental Ebola vaccine from GlaxoSmithKline GSK.L is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.

The research work is being accelerated with funding from an international consortium, reflecting mounting concern over the worst outbreak of the disease that has killed more than 1,500 people in West Africa.

Aug 28, 2014

Ebola vaccine from GSK fast-tracked into clinical trials

LONDON/NEW YORK (Reuters) – An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build a stockpile of up to 10,000 doses for emergency deployment, if results are good.

The research work is being accelerated with funding from an international consortium, reflecting mounting concern over the worst outbreak of the disease that has killed more than 1,500 people in West Africa.

Aug 28, 2014
Aug 28, 2014
Aug 26, 2014

WHO urges stiff regulatory curbs on e-cigarettes

GENEVA/LONDON, Aug 26 (Reuters) – The World Health
Organization (WHO) called for stiff regulation of electronic
cigarettes as well as bans on indoor use, advertising and sales
to minors, in the latest bid to control the booming new market.

In a long-awaited report that will be debated by member
states at a meeting in October in Moscow, the United Nations
health agency on Tuesday also voiced concern about the
concentration of the $3 billion market in the hands of big
tobacco companies.

Aug 26, 2014
Aug 25, 2014
Aug 24, 2014
Aug 24, 2014

Roche to buy U.S. biotech firm InterMune for $8.3 bln

LONDON/ZURICH, Aug 24 (Reuters) – Roche Holding AG
has agreed to buy U.S. biotech company InterMune Inc
for $8.3 billion in cash, marking the latest multibillion-dollar
deal in a consolidating pharmaceutical sector.

The Swiss drugmaker said on Sunday it would pay $74.00 a
share for InterMune, representing a premium of 38 percent to the
closing price on Aug. 22.

Aug 22, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben